After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Data from CytRx's phase III study of aldoxorubicin for the treatment of patients with soft-tissue sarcoma are being analyzed right now, with results expected toward the end of June.
Trade-Ideas LLC identified Threshold Pharmaceuticals (THLD) as a weak on high relative volume candidate
TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.